CATALOGO DEI PRODOTTI DELLA RICERCA

CAMINATI, Marco
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.797
AS - Asia 3.641
EU - Europa 2.838
SA - Sud America 506
AF - Africa 80
Continente sconosciuto - Info sul continente non disponibili 4
OC - Oceania 4
Totale 10.870
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.734
SG - Singapore 1.617
CN - Cina 1.017
IT - Italia 634
HK - Hong Kong 513
BR - Brasile 433
RU - Federazione Russa 433
FR - Francia 318
GB - Regno Unito 317
DE - Germania 308
IE - Irlanda 291
SE - Svezia 244
KR - Corea 149
VN - Vietnam 134
FI - Finlandia 110
JP - Giappone 40
IN - India 39
TG - Togo 36
NL - Olanda 34
CA - Canada 30
BD - Bangladesh 25
AT - Austria 24
AR - Argentina 23
MX - Messico 23
UA - Ucraina 22
ES - Italia 21
ID - Indonesia 21
TR - Turchia 21
PL - Polonia 20
BE - Belgio 19
ZA - Sudafrica 17
VE - Venezuela 12
CO - Colombia 10
IQ - Iraq 10
SA - Arabia Saudita 8
EC - Ecuador 7
NO - Norvegia 7
PY - Paraguay 7
CH - Svizzera 6
LT - Lituania 6
MA - Marocco 6
PE - Perù 6
UZ - Uzbekistan 6
AZ - Azerbaigian 5
CL - Cile 5
JO - Giordania 5
PK - Pakistan 5
AE - Emirati Arabi Uniti 4
BG - Bulgaria 4
JM - Giamaica 4
KE - Kenya 4
LV - Lettonia 4
BY - Bielorussia 3
CZ - Repubblica Ceca 3
OM - Oman 3
AU - Australia 2
EG - Egitto 2
EU - Europa 2
GH - Ghana 2
KG - Kirghizistan 2
LB - Libano 2
MG - Madagascar 2
NP - Nepal 2
RO - Romania 2
SK - Slovacchia (Repubblica Slovacca) 2
SN - Senegal 2
TJ - Tagikistan 2
TL - Timor Orientale 2
TT - Trinidad e Tobago 2
UY - Uruguay 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AF - Afghanistan, Repubblica islamica di 1
AO - Angola 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BJ - Benin 1
BO - Bolivia 1
BZ - Belize 1
CI - Costa d'Avorio 1
CR - Costa Rica 1
DZ - Algeria 1
GE - Georgia 1
GM - Gambi 1
GR - Grecia 1
HN - Honduras 1
HU - Ungheria 1
IL - Israele 1
IS - Islanda 1
KI - Kiribati 1
LK - Sri Lanka 1
LY - Libia 1
MD - Moldavia 1
MM - Myanmar 1
MZ - Mozambico 1
NG - Nigeria 1
NZ - Nuova Zelanda 1
PH - Filippine 1
QA - Qatar 1
RS - Serbia 1
SC - Seychelles 1
Totale 10.867
Salva come PNG Salva come JPEG
Città #
Singapore 713
Dallas 692
Chandler 603
Hong Kong 507
Dublin 286
New York 269
Southend 245
Beijing 243
Ashburn 200
Verona 125
Lawrence 120
Princeton 120
Sindelfingen 102
Wilmington 95
The Dalles 90
Jacksonville 82
Munich 79
Jinan 64
Columbus 62
Ann Arbor 56
Helsinki 53
Nanjing 47
Hebei 46
Woodbridge 46
Milan 45
Shenyang 44
Redwood City 41
Redmond 40
Turku 39
Los Angeles 38
Guangzhou 36
Lomé 35
Rome 35
São Paulo 33
Tokyo 32
Zhengzhou 32
Boardman 29
Dong Ket 29
Ho Chi Minh City 29
Bologna 27
Haikou 27
Seattle 26
Ningbo 25
Nuremberg 25
Changsha 21
Hanoi 21
Norwalk 21
Amsterdam 20
Kent 20
London 19
San Francisco 19
Santa Clara 19
Jakarta 18
Taiyuan 18
Warsaw 18
Boston 17
Brooklyn 17
Brussels 16
Council Bluffs 16
Houston 16
Taizhou 16
Tianjin 16
Frankfurt am Main 14
Hangzhou 14
Nanchang 13
Naples 13
Chennai 12
Jiaxing 12
Padova 12
Rio de Janeiro 12
Lanzhou 11
Mexico City 11
Curitiba 10
Lappeenranta 10
Moscow 10
Toronto 10
Brescia 9
Falls Church 9
Johannesburg 9
Seoul 9
Vienna 9
Bari 8
Belo Horizonte 8
Palermo 8
Porto Alegre 8
Roubaix 8
Turin 8
Brasília 7
Chicago 7
Falkenstein 7
Florence 7
Oslo 7
Tombolo 7
Treviso 7
Villarbasse 7
Delhi 6
Phoenix 6
Stockholm 6
Tashkent 6
Amman 5
Totale 6.282
Salva come PNG Salva come JPEG
Nome #
Dupilumab-induced hypereosinophilia: review of the literature and algorithm proposal for clinical management 308
Safety of Biologic Therapies for Severe Asthma: An Analysis of Adverse Reactions Reported in the WHO Pharmacovigilance Database 161
Drop-out rate among patients treated with omalizumab for severe asthma: Literature review and real-life experience 117
Asthmatic patients in COVID-19 outbreak: Few cases despite many cases 117
Periostin: The bone and beyond 114
Allergic rhinitis: pharmacotherapy in pregnancy and old age 113
Adverse reaction to local anaesthetics: Is it always allergy? 106
Allergen specific sublingual immunotherapy in children with asthma and allergic rhinitis 104
Fatal asthma; is it still an epidemic? 102
Biologics for Eosinophilic Granulomatosis with Polyangiitis: one size does not fit all 100
Asthma control in primary care: the results of an observational cross-sectional study in Italy and Spain 98
Asthma in a large COVID-19 cohort: Prevalence, features, and determinants of COVID-19 disease severity 97
Thunderstorm Asthma: A Critical Appraisal Based on Clinical Practice 93
Onset of eosinophilic granulomatosis with polyangiitis in a patient treated with an IL-5 pathway inhibitor for severe asthma 91
Allergic sensitization to common pets (cats/dogs) according to different possible modalities of exposure: an Italian Multicenter Study 90
COVID-19 in severe asthmatic patients during ongoing treatment with biologicals targeting type 2 inflammation: Results from a multicenter Italian survey 89
Importance of Cardiopulmonary Exercise Testing amongst Subjects Recovering from COVID-19 89
What lies beyond Asthma Control Test: Suggestions for clinical practice 88
Allergen Immunotherapy Adherence in the Real World: How Bad Is It and How Can It Be Improved? 87
Timing of response and long term efficacy of Omalizumab in non-clonal Mast Cell Activation Syndrome: A case series 84
Asthma and anaphylaxis 84
New horizons for the treatment of severe, eosinophilic asthma: benralizumab, a novel precision biologic 84
Omalizumab management beyond clinical trials: the added value of a network model 83
Mepolizumab for severe eosinophilic asthma: a real-world snapshot on clinical markers and timing of response 83
Asthma management among different specialists: results from a national Italian survey 83
Low adherence to inhaled corticosteroids/long-acting β2-agonists and biologic treatment in severe asthmatics 82
ALLERGY AND CORONAVIRUS DISEASE (COVID-19) INTERNATIONAL SURVEY: REAL-LIFE DATA FROM THE ALLERGY COMMUNITY DURING THE PANDEMIC 82
Biologics and global burden of asthma: A worldwide portrait and a call for action 81
Effects of specific allergen immunotherapy on biological markers and clinical parameters in asthmatic children: a controlled-real life study 80
Anti-IL-5 and IL-5Ra: Efficacy and Safety of New Therapeutic Strategies in Severe Uncontrolled Asthma 80
SANI-Severe Asthma Network in Italy: a way forward to monitor severe asthma 78
[Fractional exhaled nitric oxide measurement during specific inhalation challenge tests] 78
Anaphylaxis and intimate behaviour 78
Uncontrolled Asthma: Unmet Needs in the Management of Patients 78
COVID-19 Vaccination in Patients with Severe Asthma on Biologic Treatment: Safety, Tolerability, and Impact on Disease Control 78
Biologics for the Treatment of Allergic Conditions: Eosinophil Disorders 77
Mepolizumab 100 mg in severe asthmatic patients with EGPA in remission phase 77
Evaluation of asthma control in the pharmacy: an Italian cross-sectional study 76
Anxiety and Depression Effects During Drug Provocation Test 76
Allergy and Sexual Behaviours: an Update 76
Safety of uSCIT-MPL-4: prevalence and risk factors of systemic reactions in real life 75
COPD prevalence in a north-eastern Italian general population 74
Clinical response to biologicals for severe asthma: any relevance for sex in different age ranges? 72
Biologic Therapy in a Patient with Asthma and Nasal Polyps 72
The potential role of local pharmacies to assess asthma control: an Italian cross-sectional study 72
Relevance of TH2 markers in the assessment and therapeutic management of severe allergic asthma: A real-life perspective 71
Asthma under/misdiagnosis in primary care setting: an observational community-based study in Italy 70
Incidence and risk factors for subcutaneous immunotherapy anaphylaxis: the optimization of safety 70
Severe refractory asthma: current treatment options and ongoing research 69
Eosinophilic Granulomatosis With Polyangiitis and Cardiac Involvement: A Case Report 68
Towards precision medicine: The application of omics technologies in asthma management 68
Trends and determinants of Emergency Room admissions for asthma: A retrospective evaluation in Northeast Italy 68
Asthma management among allergists in Italy: results from a survey 68
Component resolved diagnosis (CRD): how much is it presently used by Italian allergists? 68
Efficacy of Benralizumab in severe asthma in real life and focus on nasal polyposis 68
BCG vaccination and COVID-19: Much ado about nothing? 68
Asthma control in severe asthmatics under treatment with omalizumab: A cross-sectional observational study in Italy 68
Occupational rhinitis to sodium alendronate 67
How far from correct is the use of adrenaline auto-injectors? A survey in Italian patients 67
Relationship between hair shedding and systemic inflammation in COVID-19 pneumonia 67
Biologic Therapy in a Patient with Asthma and Nasal Polyps 66
Balancing efficacy against safety in sublingual immunotherapy with inhalant allergens: what is the best approach? 66
Low‑dose anti‑IL 5 treatment in idiopathic hypereosinophilic syndrome: towards a precision medicine approach for remission maintenance 66
Successful switching from mepolizumab to dupilumab in a patient with EGPA in remission phase and persistent nasal polyposis 65
Targeting eosinophils: severe asthma and beyond 64
Quality of life in patients with food allergy 64
Comment on: Onset of eosinophilic granulomatosis with polyangiitis in a patient treated with an IL-5 pathway inhibitor for severe asthma: reply 64
Serum periostin during omalizumab therapy in asthma: A tool for patient selection and treatment evaluation 63
Prevalence and features of asthma-chronic obstructive pulmonary disease overlap in Northern Italy general population 63
Oral health in asthmatic patients: a review: Asthma and its therapy may impact on oral health 63
Hidden Comorbidities in Asthma: A Perspective for a Personalized Approach 62
Chronic Urticaria Patient Perspective (CUPP): The First Validated Tool for Assessing Quality of Life in Clinical Practice 62
Choosing wisely: practical considerations on treatment efficacy and safety of asthma in the elderly 62
Emerging drugs for allergic conjunctivitis 62
Effect of α1 Antitrypsin Deficiency on Lung Volume Decline in Severe Asthmatic Patients Undergoing Biologic Therapy 62
One-year mepolizumab for Allergic bronchopulmonary aspergillosis: Focus on steroid sparing effect and markers of response 62
Italian study on buckwheat allergy: prevalence and clinical features of buckwheat-sensitized patients in Italy 61
Sex in Respiratory and Skin Allergies 61
Clinical features associated with a doctor-diagnosis of bronchiectasis in the Severe Asthma Network in Italy (SANI) registry 60
Biologics for the Treatments of Allergic Conditions 59
Oral CorticoSteroid sparing with biologics in severe asthma: A remark of the Severe Asthma Network in Italy (SANI) 59
Premature aging of the immune system affects the response to SARS-CoV-2 mRNA vaccine in β-Thalassemia: additional dose role 56
Anaphylaxis and Coronavirus Disease 2019 vaccine: a danger relationship? 56
Idiopathic hypereosinophilic syndromes and rare dysimmune conditions associated with hyper-eosinophilia in practice: An innovative multidisciplinary approach 56
Spontaneous pneumomediastinum complicating severe acute asthma exacerbation in adult patients 56
The EAACI-AAAAI-WAO Junior Members' joint survey: A worldwide snapshot of Allergy and Clinical Immunology specialty 56
Urticaria: recommendations from the Italian Society of Allergology, Asthma and Clinical Immunology and the Italian Society of Allergological, Occupational and Environmental Dermatology 56
Benralizumab Efficacy in Late Non-Responders to Mepolizumab and Variables Associated with Occurrence of Switching: A Real-Word Perspective 55
Allergen-specific immunotherapy and COVID-19: What happened? 55
The role of the pharmacy in the management of bronchial asthma: A literature-based evaluation 55
Usefulness of basophil activation test in diagnosis of occupational nonasthmatic eosinophilic bronchitis 55
Precision Medicine in Targeted Therapies for Severe Asthma: Is There Any Place for "Omics" Technology? 54
Effects of sublingual immunotherapy on allergic inflammation: an update 54
Vitamin B12 and Atopic Dermatitis: Any Therapeutic Relevance For Oral Supplementation? 54
One year of mepolizumab. Efficacy and safety in real-life in Italy 53
Reconsidering anaphylaxis at the time of COVID-19 pandemic 53
Aspergillus fumigatus and personalized medicine: Toward a clinically reliable algorithm 52
COVID-19 pandemic and environment: Not only air pollution 52
Use of complementary medicine among patients with allergic rhinitis: an Italian nationwide survey. 52
Safety and tolerability of sublingual immunotherapy in clinical trials and real life 52
Totale 7.580
Salva come PNG Salva come JPEG
Categoria #
all - tutte 55.194
article - articoli 55.008
book - libri 0
conference - conferenze 186
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 110.388
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021495 0 0 23 83 144 77 17 23 20 9 45 54
2021/2022714 94 176 15 43 15 14 7 50 50 12 58 180
2022/20231.926 145 138 223 221 217 452 43 106 240 12 80 49
2023/20241.487 57 102 124 196 117 345 110 61 19 62 194 100
2024/20253.674 177 215 155 507 136 92 115 346 581 266 303 781
2025/20261.990 813 706 471 0 0 0 0 0 0 0 0 0
Totale 11.135